Jesper Maag
@jespermaag.bsky.social
Associate Director in Bioinformatics and Data Science at Remix Therapeutics.
Biotech. Lives in Waltham, Massachusetts.
🇸🇪
Biotech. Lives in Waltham, Massachusetts.
🇸🇪
Reposted by Jesper Maag
Announcing positive preliminary results from ongoing Phase 1 clinical trial evaluating first-in-class MYB RNA degrader, REM-422, in patients with R/M adenoid cystic carcinoma at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. #Targets25
bit.ly/4ozZes8
bit.ly/4ozZes8
October 24, 2025 at 2:03 PM
Announcing positive preliminary results from ongoing Phase 1 clinical trial evaluating first-in-class MYB RNA degrader, REM-422, in patients with R/M adenoid cystic carcinoma at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. #Targets25
bit.ly/4ozZes8
bit.ly/4ozZes8